Erlotinib Intermediate Bulk Synthesis Route & Specs
HPLC ≥99.0% Purity Verification Versus Sigma CP-335963 Lot 040M4724V
Ensuring analytical consistency is critical when sourcing a Quinazoline derivative for downstream kinase inhibitor production. Our internal quality control protocols utilize high-performance liquid chromatography (HPLC) methods validated against recognized reference standards, including Sigma CP-335963 Lot 040M4724V. This comparative analysis ensures that the chromatographic profile of our bulk material aligns with expected retention times and peak purity ratios used in major pharmaceutical R&D laboratories.
Verification focuses not only on the main peak area but also on the resolution of closely eluting impurities that may arise from incomplete cyclization or alkylation steps. While standard certificates of analysis provide baseline assay data, our engineering team performs additional system suitability tests to confirm column efficiency and detector linearity before releasing batch data. This rigorous approach minimizes the risk of false positives in purity assessment, ensuring that the industrial purity claimed reflects the actual chemical composition available for your synthesis workflow.
Erlotinib Intermediate Bulk Synthesis Route for 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
The manufacturing process for this TKI precursor typically initiates with the alkylation of 3,4-dihydroxy benzoic acid derivatives, followed by cyclization using phosphoryl trichloride (POCl3). At NINGBO INNO PHARMCHEM CO.,LTD., we optimize this synthesis route to maximize yield while controlling exothermic reactions during the chlorination phase. The use of solvents such as N,N-Dimethylformamide (DMF) or toluene is carefully managed to facilitate the formation of the 4-chloroquinazoline core.
Scale-up capability requires precise temperature control during the reflux stages to prevent the formation of dichloro-byproducts. Our manufacturing process incorporates intermediate isolation steps to remove unreacted starting materials before the final chlorination. This reduces the burden on downstream purification and ensures that the final 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline product page material meets stringent specifications for subsequent coupling reactions with aniline derivatives.
Technical Specifications: Assay Values and Physical Property Thresholds
Understanding the physical properties of the intermediate is essential for process engineering, particularly regarding dissolution rates and filtration characteristics. The following table outlines the key technical parameters monitored during production. Please note that specific numerical values may vary slightly between batches due to raw material sourcing and crystallization conditions.
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | Off-white to Light Yellow Powder | Visual Inspection |
| Assay (HPLC) | ≥99.0% (Area Normalization) | HPLC |
| Melting Point | Please refer to the batch-specific COA | Capillary Method |
| Loss on Drying | ≤0.5% | Gravimetric (105°C) |
| Particle Size (D90) | Please refer to the batch-specific COA | Laser Diffraction |
These thresholds are designed to ensure compatibility with standard reactor setups used in generic drug manufacturing. Deviations in melting point or particle size can impact the kinetics of the subsequent nucleophilic substitution reaction.
Critical COA Parameters: Residual Solvents and Heavy Metals Analysis
Residual solvent analysis is conducted in accordance with general ICH guidelines to ensure safety and process reliability. Common solvents monitored include dichloromethane, methanol, and toluene, which are frequently employed during the workup and recrystallization phases. High levels of residual POCl3 or its hydrolysis products are strictly controlled, as these can corrode equipment or interfere with catalyst performance in later steps.
Heavy metals analysis focuses on potential contaminants from reactor wear or raw material impurities. Parameters such as Lead (Pb), Arsenic (As), and Cadmium (Cd) are quantified using ICP-MS or atomic absorption spectroscopy. Maintaining low levels of these elements is vital for regulatory documentation downstream, even if the intermediate itself is not the final drug substance. Our quality assurance team reviews every batch certificate to confirm compliance with these internal safety limits before shipment.
Bulk Packaging Options and Stability Data for R&D Procurement
For R&D procurement and pilot plant trials, we offer flexible packaging solutions including 25kg fiber drums and 210L steel drums. Proper packaging is essential to maintain integrity during transit, particularly given the chemical's sensitivity to moisture. From a field engineering perspective, we must address a non-standard parameter often overlooked in basic specifications: the tendency for the material to undergo polymorphic shifts or hardening during winter shipping.
If the bulk material is exposed to sub-zero temperatures during logistics, trace moisture can lead to micro-crystallization on the particle surface, increasing cake hardness and making manual dispensing difficult. We recommend storing drums in temperature-controlled environments above 5°C to maintain free-flowing properties. This handling insight is derived from our experience with similar quinazoline structures, where thermal cycling affected bulk density and dissolution profiles upon reopening the container.
Frequently Asked Questions
What is the standard lead time for bulk orders of this intermediate?
Standard lead times vary based on current inventory levels and production scheduling. Please contact our sales team for a confirmed timeline based on your required quantity.
Can you provide custom packaging for laboratory-scale trials?
Yes, we accommodate smaller quantities for R&D purposes. Custom packaging options are available upon request to suit specific laboratory safety requirements.
Is technical documentation available for regulatory filing?
We provide comprehensive technical support including COA, SDS, and process descriptions. However, specific regulatory filings depend on the customer's jurisdiction and final drug application.
What payment terms are accepted for international shipments?
We accept standard international payment terms such as T/T and L/C. Specific terms are negotiated based on the order volume and customer credit status.
Sourcing and Technical Support
Reliable sourcing of key intermediates requires a partner with deep technical expertise and robust quality systems. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting your development pipeline with consistent quality and transparent communication. Our engineering team is available to discuss specific synthesis challenges or customization requirements for your project. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.